Skip to content

Cell Free Circulating Nucleic Acids as New Tumor Diagnostics From Human Plasma Samples.

Cell Free Circulating Nucleic Acids as New Tumor Diagnostics From Human Plasma Samples.

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04081194
Enrollment
15
Registered
2019-09-09
Start date
2016-10-01
Completion date
2019-12-01
Last updated
2019-09-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

New Tumor Diagnostics From Human Plasma Samples

Brief summary

Cell Free Circulating Nucleic Acids as New Tumor Diagnostics From Human Plasma Samples.

Detailed description

Cell free circulating free nucleic acids is new substrates for laboratory diagnostics in a number of medical areas including oncology, transfusion medicine, gynecology/obstetrics, inflammatory and autoimmune diseases etc.There are various qualities of cell free nucleic acids. In oncology, it has been shown that the early detection of cell free nucleic acids originating from the tumour preceeds the diagnostic detection of clinical relapse as done by imaging techniques or clinical symptoms by 6-8- months. Exosomes are small, lipid bilayer membrane vesicles (30-100 nm) that are released from all cell types into the extracellular space. These tiny membrane vesicles transmit EV-mediated signals by proteins, lipids, nucleic acids and sugars, and the unique molecular pattern of this package direct the type of extracellular signal to be transmitted to target cells. Interest in exosomes range from their mode of action and various functions in the body to more practical applications such as development of biomarkers based on analysis of their RNA and protein content and their use in clinical diagnostics. It was proposed that micro RNAs are transferred through exosomes to recipient cells and can there mediate repression of their mRNA targets. The use of highly expensive targeted therapies (e.g. tyrosine kinase inhibitors or PARP inhibitors) may become obsolete during therapy due to changes in the mutational molecular profile of the malignant tumour. Indeed, if early detection of cell free nucleic acids suggest therapy failure, new stratification of the patient and changed therapy modalities may be possible in the future, thus helping to prolong overall survival of tumour patients. Aims of the Research: * To isolate exosomes as a stable source of cell free nucleic acids. * To perform protein profiling on the isolated exosomes. * To isolate nucleic acids from exosomes for analysis. * To define and develop standards and protocols for cell free nucleic acids analysis particularly regarding epigenetic alterations with emphasis on DNA methylation. * Optimizing of pre-analytical process to improve the pre-analytical aspects of assays. * To test the stability of methylated compared to non-methylated circulating DNA under various pre-analytical conditions.

Interventions

None listed

Sponsors

Assiut University
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
50 Years to 90 Years
Healthy volunteers
Yes

Inclusion criteria

* patients with Melanoma

Exclusion criteria

* patients with other types of malignancies

Design outcomes

Primary

MeasureTime frameDescription
Isolation of Exosomes as a stable source of nucleic acid as an early Detection Method to diagnose Melanoma.one yearReal time PCR for detecting the presence of Melanoma relevant nucleic acids isolated of Exososmes.

Countries

Egypt

Contacts

Primary ContactSara Alameldin, Dr
dr.saraalameldin@aun.edu.eg+201007538845 -- +491577242714

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026